Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of duchenne muscular dystrophy splicing

Oligonucleotides

Volumn 20, Issue 2, 2010, Pages 69-77

  Aartsma Rus, Annemieke ^a   Houlleberghs, Hellen ^a   Van Deutekom, Judith C T ^b   Van Ommen, Gert Jan B ^a   'T Hoen, Peter A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Prosensa BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ARTICLE; CONTROLLED STUDY; DNA BASE COMPOSITION; DUCHENNE MUSCULAR DYSTROPHY; ENHANCER REGION; EXON; PRIORITY JOURNAL; RNA SPLICING; SILENCER ELEMENT; THERMODYNAMICS;

EXONS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICING;

EID: 77951959803     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2009.0215     Document Type: Article

References (23)

1. AARTSMA-RUS, A., BREMMER-BOUT, M., JANSON, A.M., DEN DUNNEN, J.T., VAN OMMEN, G.-J.B., and VAN DEUTEKOM, J.C.T. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12 (Suppl), S71-S77.
2. AARTSMA-RUS, A., DE WINTER, C.L., JANSON, A., KAMAN, W.E., VAN OMMEN, G.-J., DEN DUNNEN, J.T., and VAN DEUTEKOM, J.C.T. (2005). Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15, 284-297.
3. AARTSMA-RUS, A., FOKKEMA, I.F., VERSCHUUREN, J.J.G.M., GINJAAR, I., VAN DEUTEKOM, J.C.T., VAN OMMEN, G.-J.B., and DEN DUNNEN, J.T. (2009a). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293-299.
4. AARTSMA-RUS, A., and VAN OMMEN, G.-J.B. (2007). Anti-sense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13, 1609-1624.
5. AARTSMA-RUS, A., VAN VLIET, L., HIRSCHI, M., JANSON, A., HEEMSKERK, H., DE WINTER, C., DE KIMPE, S., VAN DEUTEKOM, J.C., 't HOEN, P., and VAN OMMEN, G.-J.B. (2009b). Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol. Ther. 17, 548-553.
6. AARTSMA-RUS, A., SINGH, K.H., FOKKEMA, I.F., GINJAAR, H.B., OMMEN, G.-J.B., DEN DUNNEN, J.T., and VANDER MAAREL, S.M. (2010). Therapeutic exon skipping for dysfer-linopathies? Eur. J. Hum. Genet. Epub Feb 10.
7. ADAMS, A.M., HARDING, P.L., IVERSEN, P.L., COLEMAN, C., FLETCHER, S., and WILTON, S.D. (2007). Antisense oli-gonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol. Biol. 8, 57.
8. DESMET, F.O., HAMROUN, D., LALANDE, M., COLLOD-́́ BEROUD, G., CLAUSTRES, M., and BEROUD, C. (2009). Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 37, e67.
9. GOYENVALLE, A., BABBS, A., VAN OMMEN, G.-J., GARCIA, L., and DAVIES, K.E. (2009). Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: promising tool for DMD therapy. Mol. Ther. 17, 1234-1240.
10. HOFFMAN, E.P., BROWN, R.H., Jr., and KUNKEL, L.M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
11. HOFFMAN, E.P., FISHBECK, K.H., BROWN, R.H., JOHNSON, M., MEDORI, R., LOIKE, J.D., HARRIS, J.B., WATERSTON, R., BROOKE, M., SPECHT, L., KUPSKY, W., CHAMBERLAIN, J., CASKEY, T., SHAPIRO, F., and KUNKEL, L.M. (1988). Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N. Engl. J. Med. 318, 1363-1368.
12. KINALI, M., ARECHAVALA-GOMEZA, V., FENG, L., CIRAK, S., HUNT, D., ADKIN, C., GUGLIERI, M., ASHTON, E., ABBS, S., NIHOYANNOPOULOS, P., GARRALDA, M.E., RUTHERFORD, M., MCCULLEY, C., POPPLEWELL, L., GRAHAM, I.R., DICKSON, G., WOOD, M.J.A., WELLS, D.J., WILTON, S.D., KOLE, R., STRAUB, V., BUSHBY, K., SEWRY, C., MORGAN, J.E., and MUNTONI, F. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918-928.
13. MATVEEVA, O.V., TSODIKOV, A.D., GIDDINGS, M., FRE-IER, S.M., WYATT, J.R., SPIRIDOROV, A.N., SHABALINA, S.A., GESTELAND, R.F., and ATKINS, J.F. (2000). Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity. Nucleic Acids Res. 28, 2862-2865.
14. MITRPANT, C., ADAMS, A.M., MELONI, P.L., MUNTONI, F., FLETCHER, S., and WILTON, S.D. (2009). Rational design of antisense oligomers to induce dystrophin exon skipping. Mol. Ther. 17, 1418-1426.
15. MONACO, A.P., BERTELSON, C.J., LIECHTI-GALLATI, S., MOSER, H., and KUNKEL, L.M. (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-95.
16. POPPLEWELL, L.J., TROLLET, C., DICKSON, G., and GRAHAM, I.R. (2009). Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol. Ther. 17, 554-561.
17. SIERAKOWSKA, H., SAMBADE, M.J., AGRAWAL, S., and KOLE, R. (1996). Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 93, 12840-12844.
18. SIRONI, M., MONOZZI, G., RIVA, L., CAGLIANI, R., COMI, G.P., BRESOLIN, N., GIORDA, R., and POZZOLI, U. (2004). Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res. 32, 1783-1791.
19. VAN DEUTEKOM, J.C., JANSON, A.A., GINJAAR, I.B., FRANKHUIZEN, W.S., AARTSMA-RUS, A., BREMMER-BOUT, M., DEN DUNNEN, J.T., KOOP, K., VAN DER KOOI, A.J., GOEMANS, N.M., DE KIMPE, S.J., EKHART, P.F., VENNEKER, E.H., PLATENBURG, G.J., VERSCHUUREN, J.J., and VAN OMMEN, G.J. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
20. VAN OMMEN, G.J., VAN DEUTEKOM, J., and AARTSMA-RUS, A. (2008). The therapeutic potential of antisense-mediated exon skipping. Curr. Opin. Mol. Ther. 10, 140-149.
21. VILLEMAIRE, J., DION, I., ELELA, S.A., and CHABOT, B. (2003). Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligo-nucleotides. J. Biol. Chem. 278, 50031-50039.
22. WEE, K.B., PRAMONO, Z.A., WANG, J.L., MACDORMAN, K.F., LAI, P.S., and YEE, W.C. (2008). Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides. PLoS One 26, e1844.
23. WILTON, S.D., FALL, A.M., HARDING, P.L., MCCLOREY, G., COLEMAN, C., and FLETCHER, S. (2007). Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol. Ther. 15, 1288-1296. (Pubitemid 46965325)